Anemia Clinical Trial
Official title:
Effect of an Integrated Educational Session on Enhancing Compliance Behavior Among Pregnant Women With Iron Deficiency Anemia
This study aimed to determine the effect of an integrated educational session on enhancing compliance behavior among pregnant women with iron deficiency anemia.The anemic pregnant women in the study group received an integrated health education in one session. While pregnant women who were allocated to the control group received the routine antenatal care and follow up.
Data collection was conducted between April 2019 and December 2019.This study was grounded in
the health compliance model(Heiby and Carlson, 1986) which proposed that elements of
engagement between health care providers and patients involve activities that are likely to
promote the development of information, produce productive emotions, and help develop the
skills required to conduct health behavior. Such aspects of engagement include the healthcare
provider listening to the patient's questions, engaging the patient in treatment decisions,
and evaluating comprehension of the patient.
For the first interview at 24 weeks' gestation, the pregnant women were re-informed about the
purpose of the study and the schedule of follow-up. The baseline data that was gathered
included test of the women's Hb levels during their routine antenatal visit,
socio-demographic characteristics, and obstetric history. Three follow-up examinations were
planned for pregnant women in both study and control groups at weeks 28, 32 and 36 of
gestation. In the study group, pregnant women with anemia obtained an integrated health
education in one session. The educational session was conducted by the principle investigator
(PI) and was steered as 40-minutes session and provided individually to every participating
woman. The content of the educational session included; disease specific knowledge, impact of
anemia on maternal and neonatal outcomes, management opportunities, effectiveness, advantages
and draw¬backs of treatment choices, iron-rich diet recognition, false eating patterns
stopping iron absorption, and healthy diet. The PI has adopted the medical recommendations
based on dietary guidelines for pregnancy(WHO, 2012). The pregnant women were given a chance
to ask questions related to the session and its content. Furthermore, women were educated in
recording all food and drink consumed inside and outside of the home, i.e. each meal/dish
they got during the reporting duration of their diary, 24 hours of recall for seven days.
They were also asked to report the exact portion size of the food by normal household
measurements (e.g. plates, pots, cups, spoons, and glasses) or by kitchen scale.
Additionally, each woman was advised to select the easiest way to remind her of her vitamin
time.
The pregnant women received an educational brochure at the end of the educational session
which included all the information given in that session written in Arabic language. The
literature-based educational brochure material was reviewed by three experts in the field of
maternity nursing prior to the distribution. Each pregnant woman in both study and control
groups was evaluated twice at 28 and 36 weeks' gestation for total dietary iron. The dietary
iron intake recorded by women has been calculated using the IRONIC-FFQ and revised, when
needed, by dietitian who was not involved in the study. In addition, the degree of the
women's adherence to medication was measured by counting the total numbers of pills consumed
between two scheduled appointments. For antenatal follow-up appointments for all women in the
study and the control groups, phone calls were given monthly and women were reminded to
record the iron intake diary seven days before their appointment. The participants returned
their supplementary bottles with any unused capsules to the PI during their monthly visits to
the antenatal clinic. Adherence to the supplementation scheme was determined based on the
number of capsules left in the package after each return visit; adherence
(percent)=[30-number of pills left in the package/number of days between the date of
dispensation and the date of return]100. The equation was adopted based on the method used
in(Cogswell et al., 2003).
At the last data collection occasion at gestation week 36, the medication adherence scale was
inserted along with check of Hb levels for all participating women. Pregnant women who were
allocated to the control group received the routine antenatal care and follow-up, but no
educational sessions or materials were provided to them
Primary Outcome:
Compliance degree
Secondary Outcome:
Iron food intake/mg, the hemoglobin level & ferritin levels
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |